Date: 2016-01-04
Type of information: Development agreement
Compound: genetically-modified fibroblasts
Company: Fibrocell Science (USA - PA) Intrexon (USA - MD)
Therapeutic area: Inflammatory diseases - Rheumatic diseases
Type agreement: development
Action mechanism: cell therapy/gene therapy
Disease:
Details: * On January 4, 2016, Fibrocell Science and Intrexon announced an exclusive channel collaboration (ECC) for the development of genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. Through the collaboration, Fibrocell’s proprietary fibroblast platform will be combined with Intrexon’s cellular engineering capabilities to generate cell-based therapeutics that have been modified to express one or more proteins at sites of joint inflammation helping overcome the limitations of existing treatment approaches for chronic inflammatory and degenerative diseases of the joint.
Financial terms: Under the terms of the agreement, Intrexon will receive a technology access fee of $10 million in cash and reimbursement for all research and development costs. The agreement also provides for regulatory and commercial milestone payments to Intrexon for each collaboration product of up to $30 million and $22.5 million, respectively, as well as a low double-digit royalty based on the net sales from collaboration products.
Latest news:
